![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number:6892D Celsis International PLC 04 October 2004 CAPITAL REORGANISATION Celsis International plc Reduction of Share Premium Account 4 October 2004: Celsis International plc announces that it is proposing to reduce its share premium account by $10,000,000 in order to increase distributable reserves for the purpose, among others, of paying dividends to shareholders. The reduction will require the approval of the Company's shareholders at an extraordinary general meeting convened for 9.00 am on 28 October 2004 at Eversheds LLP, Senator House, 85 Queen Victoria Street, London EC4V 1JL and subsequent confirmation by the Companies Court. The petition to approve the reduction of the share premium account is expected to be heard on 17 November 2004 and the reduction is expected to be effective on 19 November 2004. Copies of the circular issued by the Company in connection the reduction of share premium account have been submitted to the UK Listing Authority, and are available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at: Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS (Tel: 020 7676 1000). Enquiries: Celsis International plc Tel: 01638 600 151 Jay LeCoque, Chief Executive Officer Jenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113 David Yates Lucy Briggs Notes to editors Celsis International plc Based in Newmarket, UK, Celsis International Plc is a microbial detection and analytical services company operating through two divisions, the Product Group and the Laboratory Group. Using its proprietary enzyme technology, the Product Group is the world leader in the provision of diagnostic systems for the rapid detection of microbial contamination. It works in close collaboration with many of the world's leading pharmaceutical, personal care and beverage companies, ensuring the safety and quality of products bound for consumers. The Laboratory Group provides outsourced analytical testing services to pharmaceutical companies to ensure the stability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisions have the capacity to deliver substantial cost savings to Celsis' customers. By reducing the time it takes to test and release raw materials and finished goods to the market place, Celsis' products facilitate increased manufacturing productivity and improved supply chain management. Celsis International plc is listed on the London Stock Exchange (CEL.L). Further information can be found on the Company's website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange END MSCQZLFBZBBZFBD
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions